Mantle Cell Lymphoma
Feature
Unavoidable, random DNA replication errors are the most common cancer drivers
Up to two-thirds of the mutations that drive human cancers may be due to DNA replication errors in normally dividing stem cells, not by inherited...
Conference Coverage
Phase III trial: VZV protects auto-HCT patients
ORLANDO – An inactivated VZV vaccine for adults undergoing autologous hematopoietic stem cell transplantation has proven safe and effective.
From the Journals
For mantle cell lymphoma, VR-CAP beat R-CHOP
The difference was especially evident among patients who had a low- or medium-risk mantle cell lymphoma international prognostic index.
Conference Coverage
Ibrutinib, palbociclib yield durable complete responses in pretreated mantle cell lymphoma
SAN DIEGO – A “mechanism-based” combination of ibrutinib and palbociclib was reasonably well tolerated and induced complete responses in 44% of...
Conference Coverage
Bortezomib-based regimen led to durable remissions in mantle cell lymphoma
First-line therapy with bortezomib plus modified hyper-CVAD followed by rituximab maintenance induced durable remissions in mantle cell lymphoma...
Conference Coverage
Rituximab after ASCT boosted survival in mantle cell lymphoma
SAN DIEGO – Maintenance therapy every other month with rituximab significantly prolonged event-free and overall survival after autologous stem...
Video
VIDEO: First multicenter trial of CAR T cells shows response in DLBCL
SAN DIEGO - Aggressive, refractory non-Hodgkin lymphomas responded to anti-CD19 chimeric antigen receptor T cells in ZUMA-1, the first...
Conference Coverage
Chemo-free induction regimen shines in MCL
SAN DIEGO – A chemotherapy-free induction regimen of ibrutinib and rituximab was well tolerated and achieved an overall response rate of 100%...
Conference Coverage
Rituximab vanquished MRD in mantle cell lymphoma
SAN DIEGO – Rituximab can at least temporarily vanquish minimal residual disease in mantle cell lymphoma patients who relapse after induction...
Conference Coverage
VIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphoma
SAN DIEGO – For patients with indolent non-Hodgkin lymphoma, adding rituximab to a standard-combination chemotherapy regimen resulted in...
Conference Coverage
Antibody face-off in follicular lymphoma gives PFS, but not OS, edge to obinutuzumab
SAN DIEGO – Obinutuzumab, a second-generation anti-CD20 antibody touted as the heir apparent to rituximab, offered a PFS edge over rituximab when...